238 related articles for article (PubMed ID: 31101710)
41. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
Roberts PL; Dunkerley C; Walker C
Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
[TBL] [Abstract][Full Text] [Related]
42. Process changes and their effect on process evaluation for viral clearance.
Marcus-Sekura C
Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
[TBL] [Abstract][Full Text] [Related]
43. Use of bacteriophages as surrogates for mammalian viruses.
McAlister M; Aranha H; Larson R
Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
[TBL] [Abstract][Full Text] [Related]
44. Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration.
Nowak T; Popp B; Gröner A; Schäfer W; Kalina U; Enssle K; Roth NJ
Transfusion; 2017 May; 57(5):1184-1191. PubMed ID: 28191640
[TBL] [Abstract][Full Text] [Related]
45. Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.
Goussen C; Simoneau S; Bérend S; Jehan-Kimmel C; Bellon A; Ducloux C; You B; Paolantonacci P; Ollivier M; Burlot L; Chtourou S; Flan B
BioDrugs; 2017 Jun; 31(3):251-261. PubMed ID: 28508264
[TBL] [Abstract][Full Text] [Related]
46. [Viral safety of biological medicinal products].
Stühler A; Blümel J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1198-202. PubMed ID: 25123140
[TBL] [Abstract][Full Text] [Related]
47. RUNspike, a complementary virus filter spiking method: a solution to the problem of reduced throughput due to the addition of the virus spike.
Parrella J; Wu Y; Kahn DW; Genest P
PDA J Pharm Sci Technol; 2009; 63(6):547-58. PubMed ID: 20169861
[TBL] [Abstract][Full Text] [Related]
48. Evolution of approaches to viral safety issues for biological products.
Lubiniecki AS
PDA J Pharm Sci Technol; 2011; 65(6):547-56. PubMed ID: 22294576
[TBL] [Abstract][Full Text] [Related]
49. Meeting report--workshop on virus removal by filtration: trends and new developments.
Willkommen H; Blümel J; Brorson K; Chen D; Chen Q; Gröner A; Kreil TR; Robertson JS; Ruffing M; Ruiz S
PDA J Pharm Sci Technol; 2013; 67(2):98-104. PubMed ID: 23569071
[TBL] [Abstract][Full Text] [Related]
50. Incorporation of an additional viral-clearance step into a human immunoglobulin manufacturing process.
Van Holten RW; Ciavarella D; Oulundsen G; Harmon F; Riester S
Vox Sang; 2002 Oct; 83(3):227-33. PubMed ID: 12366764
[TBL] [Abstract][Full Text] [Related]
51. Nanofiltration of plasma-derived biopharmaceutical products.
Burnouf T; Radosevich M
Haemophilia; 2003 Jan; 9(1):24-37. PubMed ID: 12558776
[TBL] [Abstract][Full Text] [Related]
52. Virus study for continuous low pH viral inactivation inside a coiled flow inverter.
David L; Maiser B; Lobedann M; Schwan P; Lasse M; Ruppach H; Schembecker G
Biotechnol Bioeng; 2019 Apr; 116(4):857-869. PubMed ID: 30450694
[TBL] [Abstract][Full Text] [Related]
53. Inactivation of lipid enveloped viruses by octanoic Acid treatment of immunoglobulin solution.
Dichtelmüller H; Rudnick D; Kloft M
Biologicals; 2002 Jun; 30(2):135-42. PubMed ID: 12127315
[TBL] [Abstract][Full Text] [Related]
54. pH inactivation of SARS-CoV-2 and SARS-CoV in virus spiked protein A eluates from a mAb purification process.
Limburg H; Schwerdtner M; Wilson E; Roth B; Cassart JP; Werner AD; Harbig A; Böttcher-Friebertshäuser E; Stokes A
Biologicals; 2024 May; 86():101753. PubMed ID: 38492418
[TBL] [Abstract][Full Text] [Related]
55. Integrated viral clearance strategies-reflecting on the present, projecting to the future.
Roush DJ
Curr Opin Biotechnol; 2018 Oct; 53():137-143. PubMed ID: 29367164
[TBL] [Abstract][Full Text] [Related]
56. Multiplex RT Q-PCR assay for simultaneous quantification of three viruses used for validation of virus clearance by biopharmaceutical production.
Lute S; Wang H; Sanchez D; Barletta J; Chen Q; Brorson K
Biologicals; 2009 Oct; 37(5):331-7. PubMed ID: 19683941
[TBL] [Abstract][Full Text] [Related]
57. Continuous low pH viral inactivation: Operation and scaling strategy informs viral clearance study.
Brown M; Godfrey S; Creasy A; Salm J; Fahrner R
Biotechnol Bioeng; 2022 Aug; 119(8):2115-2121. PubMed ID: 35470424
[TBL] [Abstract][Full Text] [Related]
58. Multiproduct Resin Reuse for Clinical and Commercial Manufacturing-Methodology and Acceptance Criteria.
Sharnez R; Doares S; Manning S; Mehta K; Mahajan E; To A; Daniels W; Glynn J; Dhamane S; Wen X; Wang Y; Gour P; Guenther C; Foley D; Hayes R; Mott A; Prabhu S; Tavalsky D; Hendershot M; Haas D; Hesslein A; Schuelke N; Tjandra H
PDA J Pharm Sci Technol; 2018; 72(6):584-598. PubMed ID: 30030349
[TBL] [Abstract][Full Text] [Related]
59. Virus inactivation by protein denaturants used in affinity chromatography.
Roberts PL; Lloyd D
Biologicals; 2007 Oct; 35(4):343-7. PubMed ID: 17517521
[TBL] [Abstract][Full Text] [Related]
60. Real time quantitative PCR as a method to evaluate xenotropic murine leukemia virus removal during pharmaceutical protein purification.
Shi L; Chen Q; Norling LA; Lau AS; Krejci S; Xu Y
Biotechnol Bioeng; 2004 Sep; 87(7):884-96. PubMed ID: 15334415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]